Roche
Roche’s melanoma candidate impresses in phase II trials
November 5, 2010Research and Development BRAF protein, Cancer, Phase II, Plexxikon, RG7204, Roche
Roche’s mid-stage melanoma candidate has produced positive results in a difficult to treat cancer. RG7204 is an investigational, first-in-class molecule …
MabThera gains maintenance therapy licence
October 29, 2010Medical Communications, Sales and Marketing MabThera, Rituxan, Roche, lymphoma
Roche’s MabThera has been approved as a maintenance therapy for follicular lymphoma, a common type of blood cancer. Maintenance treatment …
Roche investing $180m on US diagnostics facilities
October 18, 2010Research and Development Diagnostics, Roche, Ventana, personalised medicine
Swiss drugmaker Roche is planning to invest $180 million and boost staff at its diagnostics subsidiary Ventana Medical Systems, as …
Roche revenue depressed by plummeting Tamiflu sales
October 15, 2010Sales and Marketing 2010 financials, Q3, Roche
Roche suffered a 3% drop in group revenue in the third quarter as sales of its Tamiflu plummeted by 90 …
New Herceptin data sways NICE
September 30, 2010Sales and Marketing Herceptin, NICE, Roche
NICE is now minded to approve Roche’s Herceptin for patients with metastatic gastric cancer after receiving new efficacy data from …
Future of Roche diabetes trial uncertain
September 14, 2010Research and Development GLP-1, Roche, taspoglutide
Roche has admitted it does not know when phase III trials of the investigational type II diabetes drug taspoglutide will …
Roche signs Alzheimer’s deal with reMYND
September 7, 2010Research and Development Alzheimer's, Parkinson's, Roche, reMYND
Roche has signed a deal with Belgian biotech reMYND to develop new treatments for patients with Alzheimer’s and Parkinson’s disease. …
Roche: ‘We will work to eliminate barriers to social media’
September 3, 2010Medical Communications Digital Pharma blog, Roche, social media
Last month Roche broke new ground for pharma by publishing its Social Media Principles (full details of which you can …
Roche set for jobs cuts from 2011
September 3, 2010Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Roche, job cuts
Roche has confirmed it will take wide-ranging steps to reduce costs, following local reports the Swiss pharma firm was poised …
Roche coy on job cut reports
September 1, 2010Manufacturing and Production, Research and Development, Sales and Marketing Roche, job cuts
Roche is reportedly set to cut thousands of pharma jobs to reduce costs and boost profitability following a series of …
NICE updates guidance for arthritis treatments
August 26, 2010Sales and Marketing NICE, Roche, rheumatoid arthritis
Five new drugs for rheumatoid arthritis have been given the thumbs up by NICE as second line treatment. Roche’s MabThera, …
Roche signs $1bn peptide deal with Aileron
August 25, 2010Research and Development, Sales and Marketing Aileron, Roche, peptide, stapled peptide therapeutics
Roche has entered an agreement with a US biopharma company Aileron Therapeutics to develop and commercialise drugs called Stapled Peptide …
Roche to acquire digital pathology specialists
August 23, 2010Research and Development, Sales and Marketing Diagnostics, Roche
Roche has added to its portfolio of diagnostics products by acquiring US company BioImagene. The privately held Californian company specialises …
Cell therapy industry partnership launched
August 18, 2010Research and Development Genzyme, ISCT, Lonza, Roche
Pharma and biotech companies including Roche and Genzyme are to launch a series of initiatives to bolster progress in the …
Digital Pharma: Roche asks employees to be social media ‘scouts’
August 17, 2010Medical Communications Digital Pharma blog, Roche, social media
Roche wants employees who use social media to be ‘scouts’ for how the company and its products are perceived online. …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
